An advisory panel recommends that hydrocodone be more restricted.
Panel: hydrocodone, a Schedule III drug, should be under more restrictive Schedule II.
The FDA could limit how much hydrocodone a patient could get between doctor visits.
The FDA has not said when it would act on the recommendation.
